About Calixa Therapeutics
Calixa Therapeutics is a company based in San Mateo (United States) founded in 2007 was acquired by Cubist Pharmaceuticals in December 2009.. Calixa Therapeutics has raised $30.18 million across 1 funding round from investors including Cubist Pharmaceuticals, Frazier Healthcare Partners and Canaan. Calixa Therapeutics operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter San Mateo, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Calixa Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$30.18 M (USD)
in 1 rounds
-
Latest Funding Round
$30.18 M (USD), Series A
Nov 09, 2007
-
Investors
Cubist Pharmaceuticals
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Cubist Pharmaceuticals
(Dec 14, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Calixa Therapeutics
Calixa Therapeutics has successfully raised a total of $30.18M through 1 strategic funding round. The most recent funding activity was a Series A round of $30.18 million completed in November 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $30.2M
-
First Round
First Round
(09 Nov 2007)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2007 | Amount | Series A - Calixa Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Calixa Therapeutics
Calixa Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Cubist Pharmaceuticals, Frazier Healthcare Partners and Canaan. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science & tech focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Calixa Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Calixa Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Calixa Therapeutics Comparisons
Competitors of Calixa Therapeutics
Calixa Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Calixa Therapeutics
When was Calixa Therapeutics founded?
Calixa Therapeutics was founded in 2007.
Where is Calixa Therapeutics located?
Calixa Therapeutics is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Is Calixa Therapeutics a funded company?
Calixa Therapeutics is a funded company, having raised a total of $30.18M across 1 funding round to date. The company's 1st funding round was a Series A of $30.18M, raised on Nov 09, 2007.
What does Calixa Therapeutics do?
Calixa Therapeutics is focused on the development of a novel cephalosporin against the multi-drug resistant organisms. Its lead drug is a combination of two antibacterial compounds, cephalosporin and tazobactam antibiotics. Its cephalosporin compound (dubbed CXA-101) was acquired from Japanese drugmaker Astellas Pharma. Its lead product CXA-101 is an IV formulation of a novel cephalosporin that has shown potency, especially against multi-drug resistant Pseudomonas aeruginosa. It also had plans to combine this product with a beta-lactamase inhibitor; the combination product (CXA-201) has the potential to against the infections caused by gram-negative organisms. In June 2009, Cubist Pharmaceutical acquired Calyx Therapeutics for 402.5M. Cubist Pharmaceuticals was later acquired by Merck for 9.5B.
Who are the top competitors of Calixa Therapeutics?
Calixa Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Who are Calixa Therapeutics's investors?
Calixa Therapeutics has 4 investors. Key investors include Cubist Pharmaceuticals, Frazier Healthcare Partners, Canaan, and Domain Associates.